Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:50:58.168Z.
Consensus retrieved: 2026-10-06T09:00:57.706Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:50:58.168Z.
Quote observation: 2026-10-06T14:50:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47b7d046e53ba400f53df530976eb059ace8f079140d97e9bcfa36b682aba175
Forward PE Ratio (N/A) = Dated Quote Price ($22.04) / Consensus Forward EPS ($-0.61)
FORWARD PE RATIO
N/A
Assembly Biosciences, Inc.
Market Cap
$436.67M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | $436.67M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $436.69M | 93.01 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $438.81M | N/A |
| NeuroPace, Inc. (NPCE)vs › | $439.24M | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $446.74M | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $423.29M | N/A |
| Kamada Ltd. (KMDA)vs › | $455.58M | 16.54 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.57M | N/A |
| NRC Health (NRC)vs › | $461.10M | 23.25 |
| Shoulder Innovations, Inc. (SI)vs › | $408.34M | N/A |
Trailing P/E
40.1
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $22.04, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.61 | $-1.03 – $-0.23 | 3 | n/m |
| 2027-12-31 | $-3.05 | $-5.19 – $-1.15 | 3 | n/m |
| 2028-12-31 | $-1.95 | $-5.08 – $1.28 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
